Deal facts
- Buyer
- Rockwell Medical, Inc.
- Target
- Vantive in-center hemodialysis business
- Deal value
- USD 125,000,000
- Announced
- 3 November 2026
- Status
- Firm intention
- Sector
- Healthcare
- Country
- Not stated
- Consideration
- loan-note, earn-out
Sources
Rockwell Medical, Inc. signed an Equity and Asset Purchase Agreement on November 2, 2026 with Vantive Limited, a Jersey company, to acquire Vantive's in-center hemodialysis business in 35 jurisdictions, including the United States. The business covers hemodialysis concentrates, water treatment systems, monitors, bloodlines, select price-per-treatment products and related technical services. Rockwell publicly announced the agreement on November 3, 2026 through a press release and an investor call.
The deal has two parts. Rockwell will buy all the equity of Gambro Dasco S.p.A., an Italian company that owns the business's manufacturing facility in Medolla, Italy, and of Vantive Korea Incorporated. It will also buy the business's other assets held outside those entities in other countries and assume the related liabilities, apart from specified excluded assets and liabilities that Vantive keeps. Transfer of the business in certain jurisdictions, to be designated before closing, will be deferred until local closings after the main closing. If a deferred transfer cannot be completed in time, that jurisdiction may be excluded and the term loan principal reduced.
The base purchase price is $125,000,000. The closing payment adjusts for the business's cash, net working capital and indebtedness, and for a revenue adjustment that applies only if audited 2025 net revenue falls short of the figure Rockwell was given by 20% or more. The closing consideration will be paid entirely through seller financing from Vantive affiliates: $100,000,000 of term loans in two $50,000,000 tranches, and a $25,000,000 convertible note. The note bears 3.0% interest paid in kind, matures on the sixth anniversary of closing, and converts at an initial $14.94 per share. Vantive can also earn up to $45,000,000 more, based on Rockwell's post-closing pro forma EBITDA and revenue.
Closing requires regulatory approvals, including merger control, foreign investment clearances and Italian golden power clearance. It also requires completion of Vantive's pre-closing reorganization and its separation from Baxter's information technology systems. Either party may terminate if closing has not occurred by November 1, 2027, and that date can be extended twice by 90 days each to April 29, 2028. The agreement has no termination fee or reverse termination fee, and Rockwell's obligation to close does not depend on obtaining third-party financing.
The archive tags include an earn-out. Compare completion cash, deferred payments and earn-outs before treating a headline amount as proceeds. Check the underlying announcement for the actual conditions; tags are not a complete payment schedule.
Deal timeline
1 update- Firm intention
Rockwell Medical, Inc. firm intention to acquire Vantive Limited
Item 1.01. Entry into a Material Definitive Agreement. Equity and Asset Purchase Agreement On November 2, 2026, Rockwell Medical, Inc. (the “Company”) entered into an Equity and Asset Purchase Agreement (the “Purchase Agreement”) with Vantive Limited, a company incorporated under the laws of Jersey (“Vantive”). Pursuant to the Purchase Agreement, the Company agreed to acquire Vantive’s in-center h
Source
For business owners
What would selling your own business involve?
Use the deal as a starting point, not a valuation benchmark. Learn the decisions behind a sale and apply them to your own preparation.
Guides are free to read. Free tools require email access; indicative results are not professional advice.
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
BioNTech US Inc. to acquire a Rare Pediatric Disease Priority Review Voucher from Scholar Rock Inc.
BioNTech US Inc. has agreed to buy a Rare Pediatric Disease Priority Review Voucher from Scholar Rock Inc. for $205 million in cash. Scholar Rock Inc. is a wholly owned…
- Buyer
- BioNTech US Inc.
- Target
- Rare Pediatric Disease Priority Review Voucher of Scholar Rock Inc.
- Deal value
- USD 205,000,000
- Deal type
- asset sale
Abeona Therapeutics Inc. acquires APT-1011 (ABO-801) assets of Ellodi Pharmaceuticals, L.P.
Abeona Therapeutics Inc. bought substantially all assets related to the research, development, manufacture and commercialization of APT-1011 from Ellodi Pharmaceuticals,…
- Buyer
- Abeona Therapeutics Inc.
- Target
- APT-1011 (ABO-801) assets of Ellodi Pharmaceuticals, L.P.
- Deal value
- USD 20,000,000
- Deal type
- asset sale
CorMedix Inc. to acquire substantially all assets of Heron Therapeutics, Inc.
CorMedix Inc. (Nasdaq: CRMD) and Heron Therapeutics, Inc. (Nasdaq: HRTX) announced on 9 November 2026 that they had entered into a definitive asset purchase agreement, s…
- Buyer
- CorMedix Inc.
- Target
- Substantially all assets of Heron Therapeutics, Inc.
- Deal value
- USD 222,600,000
- Deal type
- asset sale
Biossil Labs Inc. to acquire Theriva Biologics' ribaxamase and SYN-006 assets
Theriva Biologics, Inc. (NYSE American: TOVX) sold its ribaxamase program to Biossil Labs Inc., a corporation organized under the laws of Canada, under an Asset Purchase…
- Buyer
- Biossil Labs Inc.
- Target
- Theriva Biologics ribaxamase and SYN-006 assets
- Deal value
- USD 350,000
- Deal type
- asset sale
VoxelDox Therapeutics, Inc. to acquire Imunon, Inc.
VoxelDox Therapeutics, Inc. has agreed to acquire assets from Imunon, Inc. in a transaction announced on 21 October 2026. Both companies are based in the United States a…
- Buyer
- VoxelDox Therapeutics, Inc.
- Target
- Imunon, Inc.
- Deal value
- Not disclosed
- Deal type
- asset sale
Buyer history
Rockwell Medical, Inc.
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive